Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas and have provided massive savings for healthcare systems in Europe. In this exclusive interview with Adrian van den Hoven, director general of Medicines for Europe, we discuss the importance of the generic industry, the disparity in generic penetration among the member states and how the Value-Added Medicine Group will improve the lives of patients struggling to manage their disease.
An SPC manufacturing waiver should be extremely beneficial for Europe and will increase net sales of the EU pharmaceutical industry…